N,N-二甲基亮氨酰胺 | 857478-11-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N,N-二甲基亮氨酰胺
• 英文名称: N,N-Dimethylleucinamide
• 英文别名: 2-amino-N,N,4-trimethylpentanamide
• CAS: 857478-11-6
• 化学式: C₈H₁₈N₂O
• mdl: MFCD09936222
• 分子量: 158.24
• InChiKey: VINQQWZFGIKZAZ-UHFFFAOYSA-N

物化性质

• 沸点：
  234.7±23.0 °C(Predicted)
• 密度：
  0.934±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140243336A1

  公开（公告）日：2014-08-28

  The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了某些含有2-吡啶基羧酰胺的化合物，其化学式为(I)，或其药学上可接受的盐，其中A和B如本文所定义。本发明还提供了包括这些化合物的药物组合物，并且提供了使用这些化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或症状的方法。
• 3 , 5-substitued piperidine compounds as renin inhibitors
  申请人：Novartis AG

  公开号：EP2420491A1

  公开（公告）日：2012-02-22

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.

  本发明涉及3,5-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；使用该类化合物制备药物制剂，用于治疗依赖于肾素活性的疾病；该类化合物在治疗依赖于肾素活性的疾病中的用途；包含 3,5-取代的哌啶化合物的药物制剂，和/或包括施用 3,5-取代的哌啶化合物的治疗方法，3,5-取代的哌啶化合物的制造方法，及其合成的新型中间体和部分步骤。 这些化合物（也可以以盐的形式存在）具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义，R6 为 OH。
• US9216173B2
  申请人：——

  公开号：US9216173B2

  公开（公告）日：2015-12-22
• [EN] SULFONAMIDES<br/>[FR] SULFONAMIDES
  申请人：ZENECA LIMITED

  公开号：WO1998007742A1

  公开（公告）日：1998-02-26

  (EN) Compounds of formula (I) wherein R1 is aryl, heterocyclyl or heteroaryl; R2 is hydrogen, C1-8alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, heteroaryl, heterocyclyl, arylC1-6alkyl, heteroarylC1-6alkyl, heterocyclylC1-6alkyl or C3-8cycloalkylC1-6alkyl; R3 is C1-6alkyl, C2-6alkenyl, aryl, C1-6alkyl, heteroarylC1-6alkyl or the side-chain of a naturally occurring amino acid; R4 is hydrogen, C1-6alkyl, C3-8cycloalkyl, C4-8cycloalkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or heterocyclylC1-6alkyl; R5 is hydrogen or C1-6alkyl; or R4 and R5 together with the nitrogen atom to which they are joined form a heterocyclic ring; wherein any group or ring, in R1-R5, is optionally substituted; or pharmaceutically acceptable salts or $i(in vivo) hydrolysable esters thereof, are described as inhibitors of the production of Tumor Necrosis Factor and/or one or more matrix metalloproteinase enzymes. Compositions containing them and their preparation are also described.(FR) Cette invention concerne des composés de formule (I) ou leurs sels pharmaceutiquement acceptables ou leurs esters hydrolysables $i(in vivo) qui sont utiles en tant qu'inhibiteurs de la production du facteur de nécrose tumorale (TNF) et/ou d'une ou plusieurs métalloprotéases matricielles; ainsi que des compositions contenant ces composés et des procédés de préparation associés. Dans la formule (I), R1 représente aryle, hétérocyclyle ou héteroaryle; R2 représente hydrogène, alkyle C1-8, alcényle C2-6, alcynyle C2-6, cycloalkyle C3-8, hétéroaryle, hétérocyclyle, aryle alkyle C1-6, hétéroaryle alkyle C1-6, hétérocyclyle alkyle C1-6 ou cycloalkyle C3-8 alkyle C1-6; R3 représente alkyle C1-6, alcényle C2-6, aryle, alkyle C1-6, hétéroaryle alkyle C1-6 ou la chaîne latérale d'un acide aminé d'origine naturelle; R4 représente hydrogène, alkyle C1-6, cycloalkyle C3-8, cycloalcényle C4-8, aryle aryle C1-6, hétéroaryle alkyle C1-6 ou hétérocyclyle alkyle C1-6; R5 représente hydrogène ou alkyle C1-6; ou bien R4 et R5 forment un anneau hétérocyclique avec l'atome d'azote auquel ils sont liés; n'importe quel groupe ou anneau étant facultativement substitué dans R1-R5.
• [EN] ANTIMICROBIAL COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ANTIMICROBIENS ET PROCÉDÉS
  申请人：CURZA GLOBAL LLC

  公开号：WO2020150385A1

  公开（公告）日：2020-07-23

  The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.